Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
We propose to combine lapatinib with RT alone in patients with locally advanced head and neck
cancer who cannot tolerate chemotherapy. The main objective of the study is to determine the
efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression
(TTP) in this group of patients. In addition, we will determine the 2-year locoregional
control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these
patients. We will also evaluate the profile and frequency of late toxicity, specifically
mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with
locally advanced head and neck squamous cell carcinoma (HNSCC).